ArticleScientific reports2025
New insights into the mechanism of microvascular rarefaction via endothelial-mesenchymal transition in steroid-induced osteonecrosis of femoral head.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Macrophage immunometabolic reprogramming in inflammatory repair failure in osteonecrosis of the femoral head.Journal of orthopaedic translation · 2026Review
- AI-guided integration of aging-related functional assessment to predict nonresponse to cardiac rehabilitation in heart failure.The journal of nutrition, health & aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the potential role of endothelial-to-mesenchymal transition (EndMT) in steroid-induced osteonecrosis of the femoral head (SONFH), evaluate its association with microvascular rarefaction and tissue damage, and preliminarily explore whether glucocorticoid-induced oxidative stress may be involved in this process. A combination of single-cell RNA sequencing (scRNA-seq), in vitro experiments, and animal models were employed. scRNA-seq was performed on SONFH cystic lesions to identify endothelial subpopulations and trace developmental trajectories. In vitro, human umbilical vein endothelial cells (HUVECs) were treated with methylprednisolone and antioxidant (N-acetylcysteine) intervention to assess EndMT features and endothelial function. In vivo, a glucocorticoid-induced SONFH mouse model was established with or without antioxidant intervention to evaluate changes in microvascular density, EndMT occurrence, and oxidative stress levels. scRNA-seq analysis revealed endothelial subpopulations with EndMT-like features in the cystic areas of SONFH. In vitro experiments demonstrated that glucocorticoid treatment downregulated endothelial markers and upregulated mesenchymal markers in HUVECs, accompanied by impaired angiogenic function, and antioxidant therapy improves these conditions. In vivo, glucocorticoid administration led to significant microvascular rarefaction and increased EndMT marker expression in the femoral head, along with elevated oxidative stress; these changes were partially alleviated by antioxidant treatment. This study is the first to identify a potential involvement of EndMT in the pathogenesis of SONFH, highlighting its close association with microvascular rarefaction. Targeting EndMT and its upstream regulators, such as oxidative stress, may offer novel strategies for the early intervention and treatment of SONFH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.